Schneider H, Schwartzberg P L, Rudd C E
Department of Cancer Immunology and AIDS, Harvard Medical School, Boston, Massachusetts, 02115, USA.
Biochem Biophys Res Commun. 1998 Nov 9;252(1):14-9. doi: 10.1006/bbrc.1998.9559.
CTLA-4 and CD28 are differentially expressed on T-cells. They bind to a common ligand B71/2 (CD80/86), however with different avidities. Unlike CD28 which augments the T-cell response, CTLA-4 operates predominately as a negative regulator of T-cell proliferation. The mechanism by which CTLA-4 can generate these intracellular signals is unclear. Little is known regarding the identity of the protein-tyrosine kinase(s) responsible for CTLA-4 phosphorylation and thus creating conditions for the reported binding to PI 3-kinase and the protein tyrosine phosphatase SHP-2. In this study, we demonstrate that Rlk (resting lymphocyte kinase) is capable of phosphorylating CTLA-4 at the YVKM motif. Consistent with this finding, Rlk is capable of providing conditions for the binding of the SH2 domains of PI 3-kinase to the receptor. CTLA-4 is therefore the first known substrate for Rlk suggesting the possibility that this kinase may participate in CTLA-4 function.
CTLA-4和CD28在T细胞上呈差异表达。它们与共同配体B71/2(CD80/86)结合,但亲和力不同。与增强T细胞反应的CD28不同,CTLA-4主要作为T细胞增殖的负调节因子发挥作用。CTLA-4产生这些细胞内信号的机制尚不清楚。关于负责CTLA-4磷酸化从而为所报道的与PI 3激酶和蛋白酪氨酸磷酸酶SHP-2结合创造条件的蛋白酪氨酸激酶的身份知之甚少。在本研究中,我们证明Rlk(静息淋巴细胞激酶)能够在YVKM基序处磷酸化CTLA-4。与这一发现一致,Rlk能够为PI 3激酶的SH2结构域与受体的结合提供条件。因此,CTLA-4是Rlk的首个已知底物,提示该激酶可能参与CTLA-4功能的可能性。